Sacubitril/valsartan compared to ramipril in high-risk post-myocardial infarction patients stratified according to use of mineralocorticoid receptor antagonists: Insight from the PARADISE MI trial

By sjmartinez • February 21, 2024

Schou M, Claggett B, Miao ZM, Fernandez A, Filippatos G, Granger C, Jering K, Maggioni AP, McCausland F, Villota JN, Rouleau JL, Mody FV, van der Meer P, Vinereanu D, McGrath M, Zhou Y, Mann DL, Solomon SD, Steg PG, Braunwald E, McMurray JJV, Pfeffer MA, Køber L. Sacubitril/valsartan compared to ramipril in high-risk post-myocardial infarction patients stratified according to use of mineralocorticoid receptor antagonists: Insight from the PARADISE MI trial. Eur J Heart Fail. 2024 Jan;26(1):130-139. doi: 10.1002/ejhf.3079. Epub 2023 Nov 29. PMID: 37933184.

Tags: ACE inhibitors, Cardiology/Epi, drug adherence, heart failure, left ventricular dysfunction, mineralocorticoid receptor antagonists, Myorcardial infarction, Publications, sacubitril/valsartan, Veterans Administration

Related Posts

Artificial intelligence-derived splenic response in cardiac positron emission tomography is associated with major adverse cardiovascular events: a multi-site study

Ramirez G, Dharmavaram NL, Shanbhag A, Miller RJH, Kavanagh PB, Yi J, Lemley M, Builoff V, Marcinkiewicz A, Dey D, Hainer J, Wopperer S, Knight[...]

Biomarkers associated with efficacy of first-line nivolumab vs. sorafenib in advanced hepatocellular carcinoma: results from the CheckMate 459 phase III trial

Neely J, Yao J, Kudo M, Finn RS, Sangro B, Melero I, El-Khoueiry AB, Yau T, Harding JJ, Rosmorduc O, Tschaika M, Novosiadly R, Cruz[...]

Deep learning-enabled screening of chronic kidney disease from echocardiography

Yuan V, Ieki H, Sandhu A, Nguyen LH, Cheng PP, Chang ST, Ambrosy AP, Kwan AC, Go AS, Cheng S, Ouyang D. Deep learning-enabled screening[...]